MNMD240719C5000
- 1.95
- 0.000.00%
Mind Medicine Newsroom
Express News | Mind Medicine (MindMed) Inc - “at the Market Offering” Sales Agreement Prospectus Supplement Covering Offering of up to $150 Mln of Common Shares
Express News | Mind Medicine (MindMed) Inc Files for Mixed Shelf-SEC Filing
MindMed to Be Included in Russell 2000 and Russell 3000 Indexes
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced
Cantor Fitzgerald Reiterates Overweight on Mind Medicine
Cantor Fitzgerald analyst Charles Duncan reiterates Mind Medicine (NASDAQ:MNMD) with a Overweight.
MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of
MindMed Announces Constructive End-of-Phase 2 Meeting With U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)
-Aligned on requirements for Phase 3 clinical development of MM120 for the treatment of GAD- -Initiation of Phase 3 program remains on schedule to begin in second half of 2024- Mind Medicine (MindMed) Inc.
Is Mind Medicine MindMed (MNMD) Outperforming Other Medical Stocks This Year?
Leerink Partners Maintains Mind Medicine(MNMD.US) With Buy Rating
Leerink Partners analyst Rudy Li maintains $Mind Medicine(MNMD.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 36.8% and a total average return of 11.2% over the p
Baird Maintains Mind Medicine(MNMD.US) With Buy Rating, Maintains Target Price $27
Baird analyst Joel Beatty maintains $Mind Medicine(MNMD.US)$ with a buy rating, and maintains the target price at $27.According to TipRanks data, the analyst has a success rate of 46.7% and a total av
Don't Freak Out. It Isn't the End of the Line for Psychedelic Medicines. -- Barrons.com
By Josh Nathan-Kazis Turn on, tune in, drop in value. A frigid reception for one novel psychedelic treatment by a Food and Drug Administration advisory committee doesn't spell doom for all psychedel
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
A panel of advisors to the Food and Drug Administration (FDA) rejected MDMA as a treatment for post-traumatic stress disorder (PTSD) on Tuesday, citing a lack of evidence that the benefits would outwe
Psychedelic Drug Stocks Plummet On FDA Advisers' Doubts About Ecstasy Candidate -- WSJ
By Liz Essley Whyte Stocks for companies developing psychedelic treatments fell Wednesday after advisers to the Food and Drug Administration voted against a mental-health therapy using the drug MDMA,
What's Going On With MindMed And Psychedelic Stocks?
Mind Medicine (MindMed) Inc. (NASDAQ:MNMD) shares are trading lower Wednesday after a Food and Drug Administration (FDA) panel rejected the approval of MDMA therapy for people with post-traumatic stre
RBC Capital Reiterates Outperform on Mind Medicine, Maintains $22 Price Target
RBC Capital analyst Brian Abrahams reiterates Mind Medicine with a Outperform and maintains $22 price target.
Mind Medicine Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/05/2024 209.42% RBC Capital $22 → $22 Reiterates Outperform → Outperform 05/28/2024 279.75% Baird → $27
Mind Medicine Down Over 14%, on Pace for Largest Percent Decrease Since September 2022 -- Data Talk
Mind Medicine (MindMed), Inc. (MNMD) is currently at $7.09, down $1.16 or 14.06% --Would be lowest close since March 6, 2024, when it closed at $5.94 --On pace for largest percent decrease since Sep
RBC Recommends Buying MindMed Amid Psychedelic Stocks Sell-off
FDA advisory group refuses MDMA marketing authorization; psychedelic concept stocks slump.
The independent advisory group of the US FDA voted against the marketing authorization application for the psychiatric drug MDMA, causing a pre-market drop for the hallucinogenic drug developer.
Sector Update: Health Care Stocks Steady Premarket Wednesday
Health care stocks were steady premarket Wednesday with the Health Care Select Sector SPDR Fund (XLV) 0.3% higher and the iShares Biotechnology ETF (IBB) recently inactive. Vir Biotechnology (VIR) was
Mind Medicine Shares Fall After FDA Committee Votes Against Lykos Therapeutics' Psychedelic Drug
Mind Medicine's (MNMD) shares were down 9% in Wednesday's premarket activity, a day after advisers to the US Food and Drug Administration voted against Lykos Therapeutics' psychedelic drug. Lykos Ther